Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II preemptive valganciclovir treatment for CMV infection after allogeneic hematopoietic progenitor transplantation
2005-002813-19Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valganciclovir in cytomegalovirus disease (CMV), sponsored by Fundación PETHEMA. Primary endpoints: CMV negativity in blood at 2 weeks, CMV negativity in blood at end of treatment and 1 more. Started Sep 2005; status: active.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2005-002813-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002813-19.